Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKWSFI)

Drug Name

CR-002 Drug Info

Synonyms

CR-002 liquid API; Alpha 1 proteinase inhibitor (inhaled solution), CSL Behring; CR-002, CSL Behring

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Platelet-derived growth factor B (PDGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PDGF-BB	DMMBC5W	Diabetic foot ulcer	BD54	Phase 3	[3]
E-10030	DMDYWM8	Macular degeneration	9B78.3	Phase 2	[4]
GAM-501	DMAEWS1	Diabetic foot ulcer	BD54	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-derived growth factor B (PDGFB)	TTQA6SX	PDGFB_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01347190) Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis. U.S. National Institutes of Health.
2	A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44.
3	Clinical pipeline report, company report or official report of Adocia.
4	Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50.
5	Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009 Nov-Dec;17(6):772-9.